GALT [NASD]
Galectin Therapeutics Inc.
Index- P/E- EPS (ttm)-0.60 Insider Own1.10% Shs Outstand59.39M Perf Week-3.57%
Market Cap97.39M Forward P/E- EPS next Y-0.83 Insider Trans2.32% Shs Float36.30M Perf Month-1.22%
Income-35.40M PEG- EPS next Q-0.21 Inst Own12.00% Short Float5.71% Perf Quarter-6.36%
Sales- P/S- EPS this Y-26.70% Inst Trans-5.51% Short Ratio27.78 Perf Half Y0.00%
Book/sh-0.29 P/B- EPS next Y-12.20% ROA-101.70% Target Price11.00 Perf Year-55.25%
Cash/sh0.40 P/C4.02 EPS next 5Y- ROE764.80% 52W Range1.19 - 3.78 Perf YTD-21.74%
Dividend- P/FCF- EPS past 5Y7.30% ROI- 52W High-57.14% Beta1.91
Dividend %- Quick Ratio2.40 Sales past 5Y- Gross Margin- 52W Low36.13% ATR0.12
Employees9 Current Ratio2.40 Sales Q/Q- Oper. Margin- RSI (14)41.32 Volatility6.02% 7.38%
OptionableYes Debt/Eq- EPS Q/Q-11.60% Profit Margin- Rel Volume0.42 Prev Close1.66
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume74.62K Price1.62
Recom2.00 SMA20-5.95% SMA50-15.61% SMA200-8.58% Volume31,602 Change-2.41%
Aug-13-20Reiterated H.C. Wainwright Buy $9 → $12
Feb-13-19Initiated B. Riley FBR Buy $11
Dec-07-17Reiterated H.C. Wainwright Buy $6 → $10
Nov-28-17Reiterated H.C. Wainwright Buy $3.50 → $6
Oct-19-17Initiated ROTH Capital Buy
Mar-30-17Upgrade H.C. Wainwright Neutral → Buy $3.50
Oct-03-16Downgrade FBR & Co. Outperform → Mkt Perform $12 → $2
Sep-29-16Downgrade H.C. Wainwright Buy → Neutral $1.50
Sep-28-16Downgrade ROTH Capital Buy → Sell
Mar-28-16Resumed H.C. Wainwright Buy $8
Sep-21-15Initiated H.C. Wainwright Buy $7
Aug-01-14Downgrade Aegis Capital Buy → Hold
Jul-30-14Reiterated MLV & Co Buy $27 → $16
Jul-29-14Reiterated MLV & Co Buy $27 → $15
Apr-02-14Reiterated MLV & Co Buy $20 → $27
Feb-10-14Reiterated Aegis Capital Buy $16 → $32
Jan-09-14Reiterated Aegis Capital Buy $10 → $16
Dec-03-13Initiated MLV & Co Buy $20
Aug-19-13Reiterated Aegis Capital Buy $7 → $10
Sep-08-22 08:00AM
Aug-15-22 08:00AM
Jul-26-22 08:00AM
Jun-21-22 08:00AM
May-23-22 08:00AM
08:00AM Loading…
May-16-22 08:00AM
May-11-22 11:20AM
May-03-22 08:30AM
Apr-15-22 07:20AM
Apr-14-22 08:00AM
Mar-31-22 08:00AM
Jan-06-22 08:00AM
Dec-21-21 08:00AM
Dec-13-21 08:00AM
Nov-15-21 08:00AM
04:24PM Loading…
Nov-05-21 04:24PM
Oct-27-21 08:00AM
Oct-05-21 03:39PM
01:55PM
Sep-21-21 08:00AM
Sep-09-21 09:00AM
Aug-30-21 08:00AM
Aug-16-21 09:00AM
Jul-30-21 04:28AM
Jul-09-21 09:25AM
08:00AM
06:29AM
Jun-13-21 11:23PM
May-17-21 08:00AM
Apr-27-21 09:28AM
08:00AM Loading…
Apr-19-21 08:00AM
Apr-15-21 09:00AM
Apr-14-21 08:28AM
Apr-13-21 07:01PM
Apr-06-21 08:00AM
Mar-31-21 08:00AM
Mar-08-21 08:00AM
Mar-04-21 08:00AM
Jan-31-21 02:28AM
Jan-19-21 11:15AM
Dec-11-20 08:00AM
Dec-04-20 04:17PM
Dec-01-20 08:00AM
Nov-09-20 08:00AM
Nov-02-20 08:02AM
Oct-12-20 08:11AM
Oct-06-20 03:30PM
Sep-29-20 12:00PM
08:52AM
Sep-22-20 08:04AM
Sep-10-20 08:00AM
Sep-09-20 11:46AM
Sep-02-20 08:00AM
Aug-10-20 08:00AM
Aug-03-20 12:48PM
Jun-30-20 09:05AM
08:00AM
Jun-04-20 09:48PM
May-22-20 08:17AM
May-11-20 08:00AM
May-04-20 08:37AM
Apr-30-20 09:00AM
Apr-02-20 08:04AM
Mar-16-20 08:00AM
Feb-20-20 08:00AM
Feb-05-20 04:11PM
Feb-04-20 08:04AM
08:00AM
Dec-20-19 06:38PM
Dec-09-19 08:00AM
Dec-05-19 12:06PM
Nov-26-19 08:00AM
Nov-18-19 04:10PM
Nov-12-19 08:00AM
Nov-11-19 09:47AM
Nov-05-19 08:00AM
Oct-28-19 08:39AM
Sep-17-19 08:00AM
Sep-11-19 10:13AM
Aug-27-19 03:21PM
10:21AM
09:00AM
Aug-09-19 08:00AM
Aug-07-19 11:20AM
11:15AM
Aug-06-19 10:51AM
Aug-05-19 08:05AM
May-28-19 09:05AM
May-27-19 08:44AM
May-23-19 05:30PM
May-10-19 08:05AM
08:00AM
Apr-15-19 08:00AM
Apr-02-19 08:00AM
Mar-22-19 10:19AM
Mar-06-19 11:34AM
08:03AM
08:02AM
08:00AM
Feb-26-19 07:25AM
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zordani Richard A. Jr.DirectorJul 28Buy2.505,00012,50029,583Jul 29 09:11 AM
FREEMAN KEVIN DDirectorMay 19Buy1.335,0006,65065,000May 20 07:30 AM
FREEMAN KEVIN DDirectorApr 18Buy1.715,0008,55060,000Apr 18 03:59 PM
Zordani Richard A. Jr.DirectorApr 04Buy1.605,0008,02524,583Apr 04 02:58 PM
10X Fund, L.P.10% OwnerFeb 02Sale2.1010,00021,0006,178,940Feb 04 06:23 PM
Schwartz Elissa J.DirectorJan 21Buy2.001,0002,0001,000Jan 24 08:42 AM
FREEMAN KEVIN DDirectorJan 19Buy1.965,0009,80650,000Jan 19 11:02 AM
Zordani Richard A. Jr.DirectorJan 14Buy2.025,00010,10019,583Jan 18 08:54 AM
10X Fund, L.P.10% OwnerJan 11Sale2.1010,00021,0006,188,940Jan 13 03:42 PM
FREEMAN KEVIN DDirectorDec 06Buy2.285,00011,40050,000Dec 15 04:25 PM
FREEMAN KEVIN DDirectorDec 06Buy2.345,00011,70045,000Dec 06 02:09 PM
10X Fund, L.P.10% OwnerDec 02Sale2.3710,00023,7006,198,940Dec 06 12:42 PM
10X Fund, L.P.10% OwnerNov 01Sale3.1910,00031,9006,208,940Nov 04 11:55 AM
FREEMAN KEVIN DDirectorOct 29Buy3.172,0006,34040,000Nov 01 12:51 PM
FREEMAN KEVIN DDirectorOct 21Buy3.192,0006,38038,000Oct 21 12:52 PM
FREEMAN KEVIN DDirectorOct 19Buy3.373,00010,10736,000Oct 19 02:14 PM
10X Fund, L.P.10% OwnerOct 15Sale3.3710,00033,7006,218,940Oct 19 03:18 PM